Skip to main content
. Author manuscript; available in PMC: 2022 Mar 30.
Published in final edited form as: Circulation. 2021 Jan 21;143(13):1317–1330. doi: 10.1161/CIRCULATIONAHA.120.051517

Figure 4. Htr2b deletion in resident cardiac fibroblasts (CFs) abates impact of myocardial infarction (MI).

Figure 4.

A, Left Schematic illustrating the Tcf21 locus harboring a tamoxifen-inducible MerCreMer (MCM) cDNA, tdTomato reporter in the Rosa26 locus preceded by a loxP-flanked stop codon, and a loxP-flanked Htr2b target allele. Middle Experimental timeline for 16–17-week-old mice. Right Key. B, Left ventricular ejection fraction (LV EF). C, Left ventricular fractional shortening (LV FS). D,E, Left ventricular internal dimension at end-diastole (LVID;d) and end-systole (LVID;s). F,G, Left ventricular volume at end-diastole (LV Vol;d) and end-systole (LV Vol;s). H, Global longitudinal strain (GLS). I, Heart weight (HW) normalized to tibia length (TL). B-I, Mean ± SEM, *P<0.05, **P<0.01, ***P<0.001 between Htr2bfl/fl and Htr2bfl/flTcf21MCM/+ animals, #P<0.05, ##P<0.01 between timepoints within genotype following (B-H) 2-way ANOVA and Holm-Sidak post hoc test or (I) 2-tailed Student t test. Number of mice analyzed denoted in B applies to all subsequent data.